> top > docs > PubMed:32965395 > annotations

PubMed:32965395 JSONTXT

Annnotations TAB JSON ListView MergeView

ENG_NER_NEL_CONSENSUS

Id Subject Object Predicate Lexical cue
T11 561-569 MESH:D010361 denotes patients
T12 599-610 CHEBI:64360 denotes tocilizumab
T14 736-744 DOID:0080600 denotes COVID-19
T16 796-823 MESH:D016449 denotes randomized controlled trial
T17 858-869 CHEBI:64360 denotes tocilizumab
T19 925-933 MESH:D010361 denotes patients
T20 939-947 HP:0012826 denotes moderate
T21 951-957 HP:0012828 denotes severe
T22 958-966 DOID:0080600 denotes COVID-19
T24 1091-1099 CHEBI:82594 denotes ferritin
T25 1116-1123 CHEBI:24996 denotes lactate
T27 1285-1293 DOID:0080600 denotes COVID-19
T3 376-380 CHEBI:50906 denotes role
T31 1586-1592 MESH:D001938 denotes Brazil
T32 1742-1748 MESH:D016454 denotes review
T34 1969-1977 DOID:0080600 denotes COVID-19
T36 1978-1986 MESH:D010361 denotes patients
T37 422-430 DOID:0080600 denotes COVID-19
T38 438-465 CHEBI:67079 denotes anti-inflammatory therapies
T39 683-697 MESH:D015850 denotes interleukin-6,
T4 376-380 MESH:D012380 denotes role
T40 736-744 HP:0033141 denotes COVID-19
T41 958-966 HP:0033141 denotes COVID-19
T42 1285-1293 HP:0033141 denotes COVID-19
T43 1969-1977 HP:0033141 denotes COVID-19
T44 518-551 GO:0002526 denotes uncontrolled inflammatory cascade
T45 422-430 MESH:D000086742 denotes COVID-19
T46 736-744 MESH:D000086742 denotes COVID-19
T47 958-966 MESH:D000086742 denotes COVID-19
T48 1285-1293 MESH:D000086742 denotes COVID-19
T49 1969-1977 MESH:D000086742 denotes COVID-19
T5 388-395 DOID:4 denotes disease
T50 1062-1080 MESH:D002097 denotes C reactive protein
T51 1091-1099 MESH:D005293 denotes ferritin
T52 1944-1965 GO:0006954 denotes inflammatory response
T6 388-395 MESH:D004194 denotes disease
T7 396-404 HP:0012824 denotes severity
T8 408-416 MESH:D010361 denotes patients
T9 422-430 HP:0033141 denotes COVID-19

ENG_RE_CONSENSUS

Id Subject Object Predicate Lexical cue
T0 376-380 CHEBI_50906 denotes role
T1 388-395 DOID_4 denotes disease
T2 396-404 HP_0012824 denotes severity
T18 422-430 HP_0033141 denotes COVID-19
T3 422-430 DOID_0080600 denotes COVID-19
T16 438-465 CHEBI_67079 denotes anti-inflammatory therapies
T17 518-551 GO_0002526 denotes uncontrolled inflammatory cascade
T4 599-610 CHEBI_64360 denotes tocilizumab
T19 736-744 HP_0033141 denotes COVID-19
T5 736-744 DOID_0080600 denotes COVID-19
T6 858-869 CHEBI_64360 denotes tocilizumab
T7 939-947 HP_0012826 denotes moderate
T8 951-957 HP_0012828 denotes severe
T20 958-966 HP_0033141 denotes COVID-19
T9 958-966 DOID_0080600 denotes COVID-19
T10 1091-1099 CHEBI_82594 denotes ferritin
T11 1116-1123 CHEBI_24996 denotes lactate
T21 1285-1293 HP_0033141 denotes COVID-19
T12 1285-1293 DOID_0080600 denotes COVID-19
T13 1545-1552 HP_0030645 denotes central
T14 1944-1965 GO_0006954 denotes inflammatory response
T22 1969-1977 HP_0033141 denotes COVID-19
T15 1969-1977 DOID_0080600 denotes COVID-19
R10 T3 T6 effect COVID-19,tocilizumab
R11 T3 T10 effect COVID-19,ferritin
R12 T3 T11 effect COVID-19,lactate
R13 T5 T0 no_relation COVID-19,role
R14 T5 T4 effect COVID-19,tocilizumab
R15 T5 T6 effect COVID-19,tocilizumab
R16 T5 T10 effect COVID-19,ferritin
R17 T5 T11 effect COVID-19,lactate
R18 T9 T0 no_relation COVID-19,role
R19 T9 T4 effect COVID-19,tocilizumab
R2 T14 T8 no_relation inflammatory response,severe
R20 T9 T6 effect COVID-19,tocilizumab
R21 T9 T10 effect COVID-19,ferritin
R22 T9 T11 effect COVID-19,lactate
R23 T12 T0 no_relation COVID-19,role
R24 T12 T4 effect COVID-19,tocilizumab
R25 T12 T6 no_relation COVID-19,tocilizumab
R26 T12 T10 no_relation COVID-19,ferritin
R27 T12 T11 no_relation COVID-19,lactate
R28 T15 T0 no_relation COVID-19,role
R29 T15 T4 effect COVID-19,tocilizumab
R30 T15 T6 no_relation COVID-19,tocilizumab
R31 T15 T10 no_relation COVID-19,ferritin
R32 T15 T11 no_relation COVID-19,lactate
R4 T1 T4 effect disease,tocilizumab
R5 T1 T6 effect disease,tocilizumab
R6 T1 T10 effect disease,ferritin
R7 T1 T11 effect disease,lactate
R8 T3 T0 no_relation COVID-19,role
R9 T3 T4 effect COVID-19,tocilizumab
R33 T16 T17 effect anti-inflammatory therapies,uncontrolled inflammatory cascade
R34 T8 T20 effect severe,COVID-19
R35 T7 T20 effect moderate,COVID-19
R36 T7 T9 effect moderate,COVID-19
R37 T8 T9 effect severe,COVID-19
R38 T22 T14 effect COVID-19,inflammatory response
R39 T15 T14 effect COVID-19,inflammatory response
R0 T14 T2 no_relation inflammatory response,severity
R1 T14 T7 no_relation inflammatory response,moderate

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-153 Sentence denotes Rationale and design of the "Tocilizumab in patients with moderate to severe COVID-19: an open-label multicentre randomized controlled" trial (TOCIBRAS).
T2 154-317 Sentence denotes Justificativa e delineamento do estudo “Tocilizumabe em pacientes com COVID-19 moderado a grave: estudo aberto, multicêntrico, randomizado, controlado” (TOCIBRAS).
T3 318-331 Sentence denotes INTRODUCTION:
T4 332-431 Sentence denotes Pro-inflammatory markers play a significant role in the disease severity of patients with COVID-19.
T5 432-570 Sentence denotes Thus, anti-inflammatory therapies are attractive agents for potentially combating the uncontrolled inflammatory cascade in these patients.
T6 571-745 Sentence denotes We designed a trial testing tocilizumab versus standard of care intending to improve the outcomes by inhibiting interleukin-6, an important inflammatory mediator in COVID-19.
T7 746-767 Sentence denotes METHODS AND ANALYSIS:
T8 768-967 Sentence denotes This open-label multicentre randomized controlled trial will compare clinical outcomes of tocilizumab plus standard of care versus standard of care alone in patients with moderate to severe COVID-19.
T9 968-1162 Sentence denotes Two of the following four criteria are required for protocol enrolment: D-dimer > 1,000ng/mL; C reactive protein > 5mg/dL, ferritin > 300mg/dL, and lactate dehydrogenase > upper limit of normal.
T10 1163-1311 Sentence denotes The primary objective will be to compare the clinical status on day 15, as measured by a 7-point ordinal scale applied in COVID-19 trials worldwide.
T11 1312-1470 Sentence denotes The primary endpoint will be assessed by an ordinal logistic regression assuming proportional odds ratios adjusted for stratification variables (age and sex).
T12 1471-1496 Sentence denotes ETHICS AND DISSEMINATION:
T13 1497-1660 Sentence denotes The TOCIBRAS protocol was approved by local and central (national) ethical committees in Brazil following current national and international guidelines/directives.
T14 1661-1793 Sentence denotes Each participating center had the study protocol approved by their institutional review boards before initiating protocol enrolment.
T15 1794-1871 Sentence denotes The data derived from this trial will be published regardless of the results.
T16 1872-2023 Sentence denotes If proven active, this strategy could alleviate the consequences of the inflammatory response in COVID-19 patients and improve their clinical outcomes.
T1 0-153 Sentence denotes Rationale and design of the "Tocilizumab in patients with moderate to severe COVID-19: an open-label multicentre randomized controlled" trial (TOCIBRAS).
T2 154-317 Sentence denotes Justificativa e delineamento do estudo “Tocilizumabe em pacientes com COVID-19 moderado a grave: estudo aberto, multicêntrico, randomizado, controlado” (TOCIBRAS).
T3 318-331 Sentence denotes INTRODUCTION:
T4 332-431 Sentence denotes Pro-inflammatory markers play a significant role in the disease severity of patients with COVID-19.
T5 432-570 Sentence denotes Thus, anti-inflammatory therapies are attractive agents for potentially combating the uncontrolled inflammatory cascade in these patients.
T6 571-745 Sentence denotes We designed a trial testing tocilizumab versus standard of care intending to improve the outcomes by inhibiting interleukin-6, an important inflammatory mediator in COVID-19.
T7 746-767 Sentence denotes METHODS AND ANALYSIS:
T8 768-967 Sentence denotes This open-label multicentre randomized controlled trial will compare clinical outcomes of tocilizumab plus standard of care versus standard of care alone in patients with moderate to severe COVID-19.
T9 968-1162 Sentence denotes Two of the following four criteria are required for protocol enrolment: D-dimer > 1,000ng/mL; C reactive protein > 5mg/dL, ferritin > 300mg/dL, and lactate dehydrogenase > upper limit of normal.
T10 1163-1311 Sentence denotes The primary objective will be to compare the clinical status on day 15, as measured by a 7-point ordinal scale applied in COVID-19 trials worldwide.
T11 1312-1470 Sentence denotes The primary endpoint will be assessed by an ordinal logistic regression assuming proportional odds ratios adjusted for stratification variables (age and sex).
T12 1471-1496 Sentence denotes ETHICS AND DISSEMINATION:
T13 1497-1660 Sentence denotes The TOCIBRAS protocol was approved by local and central (national) ethical committees in Brazil following current national and international guidelines/directives.
T14 1661-1793 Sentence denotes Each participating center had the study protocol approved by their institutional review boards before initiating protocol enrolment.
T15 1794-1871 Sentence denotes The data derived from this trial will be published regardless of the results.
T16 1872-2023 Sentence denotes If proven active, this strategy could alleviate the consequences of the inflammatory response in COVID-19 patients and improve their clinical outcomes.